Classification: Growth Hormone Releasing Peptide Blend
Active substances:
- Ipamorelin 5 mg
- Tesamorelin 5 mg
Manufacturer: Dragon Pharma
Form/Strength: Lyophilized Powder/10 mg per vial (5mg each)
Pack size: 10 mg vial (2 mL)
Route: Subcutaneous Injection
Dragon Pharma's innovative Ipamorelin/Tesamorelin blend represents the pinnacle of growth hormone optimization technology. This powerful 5mg/5mg combination leverages the unique strengths of both peptides to create a synergistic effect that surpasses what either compound can achieve alone. Specifically formulated for athletes seeking superior body composition changes, this blend targets stubborn fat reduction while promoting lean muscle preservation and enhanced recovery.
This advanced peptide combination brings together two of the most effective growth hormone secretagogues available. Ipamorelin provides selective growth hormone release without affecting cortisol or prolactin levels, while Tesamorelin offers potent GH stimulation with specific affinity for abdominal fat reduction. According to research published in the Journal of Clinical Endocrinology & Metabolism, Tesamorelin has demonstrated significant efficacy in reducing visceral adipose tissue while improving lipid profiles, making this combination ideal for physique enhancement.
The Dragon Pharma Ipamorelin/Tesamorelin blend delivers comprehensive benefits that address multiple aspects of performance and body composition:
Proper dosing is crucial for maximizing the synergistic benefits of this advanced peptide blend. Reconstitute with bacteriostatic water using gentle swirling motion until fully dissolved. Recommended dosing strategies include:
Administer subcutaneous injections in abdominal tissue on an empty stomach, ideally before bedtime or upon waking. Rotation of injection sites prevents tissue irritation. The balanced Ipamorelin/Tesamorelin price & protocol makes this combination cost-effective compared to purchasing each peptide separately.
This sophisticated blend operates through complementary mechanisms that enhance growth hormone release while minimizing side effects. Ipamorelin functions as a selective ghrelin receptor agonist that stimulates GH release without affecting other pituitary hormones. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that provides sustained GH stimulation. Together, they create a powerful pulsatile GH release that mimics natural secretion patterns while specifically targeting fat metabolism pathways.
Both components of this blend have substantial clinical research supporting their efficacy. Tesamorelin received FDA approval for treating HIV-associated lipodystrophy due to its remarkable ability to reduce abdominal fat. Ipamorelin has been extensively studied for its selective GH-releasing properties and excellent safety profile. The combination represents an advanced approach to physique enhancement that leverages pharmaceutical-grade research for athletic applications.
Cycles typically range from 8-16 weeks, with longer cycles possible due to the excellent safety profile of both peptides. Effective protocols include:
Post-cycle therapy is generally not required with peptides alone, but monitoring and gradual tapering are recommended.
The Ipamorelin/Tesamorelin blend is exceptionally well-tolerated with minimal side effects reported:
These effects are generally mild and dose-dependent. The excellent safety profile makes this combination suitable for extended use under proper guidance.
Dragon Pharma maintains pharmaceutical-grade manufacturing standards for this advanced peptide blend, ensuring:
This commitment to quality guarantees consistent, reliable results with every vial. The competitive Ipamorelin/Tesamorelin price & protocol makes advanced peptide therapy accessible to serious athletes.
Unreconstituted vials should be stored refrigerated at 2-8°C (36-46°F) in their original packaging. After reconstitution with bacteriostatic water, the solution remains stable for 4-6 weeks when refrigerated. Avoid freezing, temperature extremes above 25°C (77°F), or direct light exposure. Always use aseptic technique when handling and administering to maintain sterility.
This advanced peptide combination offers distinct advantages for athletes and individuals seeking optimal body composition:
For those committed to achieving their peak physique, Dragon Pharma's Ipamorelin/Tesamorelin blend represents a scientifically advanced approach to growth hormone optimization with targeted fat-reduction benefits.
The combination provides synergistic benefits that surpass individual use. Ipamorelin offers selective GH release without affecting other hormones, while Tesamorelin provides potent GH stimulation with specific affinity for abdominal fat reduction. Together, they create a more comprehensive effect on both body composition and metabolic health. Users typically experience better fat loss results with the blend compared to either peptide alone.
Pre-bedtime injections are generally most effective, as they align with the body's natural GH pulse during deep sleep. Some users also benefit from morning injections upon waking. The key is administering on an empty stomach (at least 30 minutes before eating or 2 hours after meals) to maximize GH response. Consistency in timing helps establish optimal secretion patterns.
Yes, this blend is generally well-tolerated by female users. Women should start at the lower end of the dosage range (100-150 mcg daily) and monitor their response. The combination is particularly beneficial for women seeking abdominal fat reduction and improved body composition without the androgenic side effects associated with traditional performance compounds.
Most users begin noticing changes in body composition within 4-6 weeks, with significant abdominal fat reduction typically apparent after 8-12 weeks of consistent use. The rate of results depends on factors including dosage, diet, training intensity, and individual responsiveness. Tesamorelin's specific affinity for visceral fat makes this blend particularly effective for stubborn abdominal areas.
Yes, both Ipamorelin and Tesamorelin have excellent safety profiles suitable for extended use. Many clinical studies involve continuous use for 6-12 months without significant side effects. However, cycling (8-16 weeks on, 4-8 weeks off) may help maintain optimal responsiveness. Regular monitoring and appropriate dosing are key to long-term success.
Please log in to write Ipamorelin 5 mg/Tesamorelin 5 mg review.
Classification: Growth Hormone Secretagogue (GHRP)
Active substance: Ipamorelin
Manufacturer: Dragon Pharma
Form/Strength: Lyophilized Powder, 5 mg/vial
Pack size: 2 mL Vial
Route: Subcutaneous (SC) Injection
Lab Test: View Result
Classification: Synthetic Melanocortin Peptide
Active substance: Melanotan II
Manufacturer: Dragon Pharma
Form/Strength: Lyophilized Powder / 10 mg per vial
Pack size: 2 mL Vial
Route: Subcutaneous Injection (Reconstituted with Bacteriostatic Water)
Lab Test: View Result
Classification: Metabolic Peptide (GLP-1/GIP Receptor Agonist)
Active substance: Tirzepatide
Manufacturer: Dragon Pharma
Form/Strength: Lyophilized Powder, 5 mg/vial
Pack size: 2 mL Vial
Route: Subcutaneous Injection (Reconstitution Required)
Lab Test: View Result
Classification: Nootropic Peptide
Active substance: Semax
Manufacturer: Dragon Pharma
Form/Strength: Lyophilized Powder / 5 mg per 2 mL vial
Pack size: 1 Vial
Route: Intranasal or Subcutaneous
Lab Test: View Result